Cancer Advances, Inc.

Cancer Advances, Inc. is a clinical-stage biopharmaceutical company based in Durham, North Carolina, in the United States. The company is focused on developing therapeutics for gastrointestinal cancers and other cancers, with a particular emphasis on tumors that produce gastrin or express the gastrin receptor (CCKB). Its stated goal is to improve the quality of life and extend the survival of patients with gastrointestinal cancers by enhancing the adaptive immune system and preventing cancer progression. The company's lead product is the Polyclonal Antibody Stimulator (PAS), described as an immunomodulator that blocks the function of gastrin. According to the company, this inhibition slows tumor growth, reduces the incidence of metastasis, and changes the tumor microenvironment. PAS is a vaccine that has been studied in multiple clinical trials involving over 1,500 subjects and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is developing it for gastric, pancreatic, colorectal, and liver cancers, as well as exploring synergy between treatment classes. Recent nonclinical research suggests that PAS may increase the efficacy of PD-1 checkpoint inhibitors by turning pancreatic cancer tumors from "cold" to "hot." Cancer Advances has cultivated an intellectual property portfolio that includes over 100 United States and worldwide patents related to PAS, along with a trademark portfolio and strategy. The company is a wholly owned subsidiary of Cato BioVentures and is led by a seasoned management team with more than 100 years of combined industry experience. Lynda Sutton serves as President of Cancer Advances and is also President and Chief Regulatory Officer for Cato Research. The company is headquartered at the Westpark Corporate Center, 4364 South Alston Avenue, Suite 105, Durham, North Carolina 27713.

Cancer Advances, Inc. is a clinical-stage biopharmaceutical company headquartered in Durham, North Carolina. It operates as a wholly owned subsidiary of Cato BioVentures, a life sciences investment and management firm. The company was established to develop therapeutics for gastrointestinal cancers and other cancers, with a focus on enhancing the adaptive immune system to prevent cancer progression. The company's founding year is not specified in the available evidence. Its lead product, the Polyclonal Antibody Stimulator (PAS), is an immunomodulator that blocks the function of gastrin, a hormone that can stimulate tumor growth. PAS has been studied in multiple clinical trials involving over 1,500 subjects, demonstrating an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and has built an intellectual property portfolio of over 100 United States and worldwide patents related to the product, along with a trademark portfolio and strategy. The company is led by a seasoned management team with more than 100 years of combined industry experience. Lynda Sutton serves as President of Cancer Advances and also holds the positions of President and Chief Regulatory Officer at Cato Research. Under her leadership, the company has focused on developing PAS for gastric, pancreatic, colorectal, and liver cancers, and on exploring synergy between treatment classes. Recent nonclinical research suggests that PAS can increase the efficacy of PD-1 checkpoint inhibitors by turning pancreatic cancer tumors from "cold" to "hot." As of 2024, Cancer Advances continues to advance its clinical programs and intellectual property, aiming to improve the quality of life and extend the survival of patients with gastrointestinal cancers. The company is located at the Westpark Corporate Center, 4364 South Alston Avenue, Suite 105, Durham, North Carolina 27713.

Clinical-stage biopharmaceutical company focused on immunomodulatory therapeutics for gastrointestinal cancers, with a proprietary lead candidate and extensive patent portfolio.

• Polyclonal Antibody Stimulator (PAS)

  An immunomodulator vaccine that blocks the function of gastrin, slowing tumor growth, reducing metastasis, and changing the tumor microenvironment. Studied in multiple clinical trials in over 1,500 subjects.

1. 1Cancer Advancescanceradvances.com
2. 2About | Cancer Advancescanceradvances.com
3. 3Cancer Advances, Inc. (United States) - Wikidatawikidata.org